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Summary
The advent of stents has profoundly changed percutaneous transluminal coronary angioplasty (PTCA), peripheral transluminal artery
angioplasty (PTA), and treatment strategies of numerous other problems. Similar developments can be observed for stent applications in
peripheral vascular lesions, cerebro-vascular disease, and many other fields. With the advent of covered stent-grafts, aneurysm surgery, has
been put up for competitive treatment approaches. Such new approaches are perceived as less invasive, and draw significant attention.
Endovsacular aneurysm repair (EVAR) is here to stay. In addition new developments are coming in many ways and stent derived devices can by
now be found everywhere in the cardio-vascular system. This includes stenosed vessels, aneurysmal vessels, diseased valves, all sorts of
congenital heart defects, and even cardiopulmonary bypass. The key technologies and know-how for EVAR are available or can be made
available in most cardio-vascular surgical units. Special interest in this field (clinical and/or experimental) can enhance recruitment of patients.
The opposite is also true.
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The advent of stents has profoundly changed percuta-
neous transluminal coronary angioplasty (PTCA), peripheral
transluminal artery angioplasty (PTA), and treatment strat-
egies of numerous other problems.
As a matter of fact, stent-based treatments of coronary
artery stenoses are by now in many countries far more
frequent than the formerly so successful coronary artery
bypass graft (CABG) procedures. This development has
occurred despite the fact, that traditional left internal
thoracic artery to the left anterior descending coronary
artery implants have the best long-term patency, and that
coronary artery bypass graft (CABG) procedures provide
superior long-term outcome with less adverse events. In
addition, off-pump coronary artery bypass (OPCAB) allowing
for elimination of pump related events, did not substantially
change the increased use of the even lesser invasive stent-
based treatments strategies.
Similar developments can be observed for stent appli-
cations in peripheral vascular lesions, cerebro-vascular
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addition, a number of stent-derived treatment modalities are
proposed, and used in increasing proportions for closure of
the patent ductus arteriosus, foramen ovale, atrial septal
defects, ventricular septal defects, etc. Despite non-negli-
gible complication rates and incomplete treatments, percu-
taneous procedures are overall far more popular among both,
doctors and patients.
With the advent of covered stent-grafts, yet another field
of cardio-vascular surgery, namely aneurysm surgery, has
been put up for competitive treatment approaches, and
once again, the new approach is perceived as less invasive,
and draws significant attention.2. Impact in general
Thoracic aortic aneurysm and thoracic aortic dissection
repair has traditionally been an almost exclusive domain of
cardiac and cardio-vascular surgery. However, this activity
based on open surgery with and without adjuncts (cardio-
pulmonary bypass, deep hypothermic circulatory arrest, left
heart bypass, selective perfusion, etc.) is more and more
under attack by (non-)surgical experts promoting endo-
vascular aneurysm repair based on covered stent-grafts.
There are number of reasons for this development, but
some of them are difficult to understand. The theoretical
and practical know-how for EndoVascular Aneurysm Repair
(EVAR) by the means of covered stent-grafts was and isEuropean Journal of Cardio-thoracic Surgery 26 (2004) S14–S18www.elsevier.com/locate/ejcts
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daily routines include implantation of intra-aortic balloons,
percutaneous cannulation, pacemaker and defibrillator
implantation with epicardial and trans-venous leads, inser-
tion of caval filters, per-procedural angiography, etc. These
techniques require not only intimate knowledge of the
material necessary for the mentioned procedures but also
regular practice with the Seldinger catheter technique,
fluoroscopy, ultrasound, and other imaging equipment.
However, most surgeons have not been among the early
adopters of endo-vascular aneurysm repair. Hence, many
specialists from other fields with helpful diagnostic and/or
therapeutic skills, like angiologists, cardiologists, neurol-
ogists, radiologists, and vascular surgeons, got interested in
EVAR before the cardio-vascular surgeons, and, as a result,
increased competition between procedures first, and for
patients, second, occurred.Fig. 1. Mobile cart with the most frequently used guide-wires, introducers,
catheters, and other ancillary equipment for EVAR in the operating theatre.3. Impact in Lausanne
Out of the 30,000 patients registered in our database, 985
cases suffered from abdominal aortic aneurysms (3.2%), 466
for ascending aortic aneurysms (1.5%), 219 for type A aortic
dissections (0.7%), 197 for descending thoracic and thoraco-
abdominal aortic aneurysms (0.6%), 110 for peripheral
arterial aneurysms (0.4%), and 56 for type B aortic dissec-
tions (0.2%) (all aneurismal lesionsZ6.6% of our case load).
Over the last 10 years (13,182 cases), abdominal aortic
aneurysms accounted for 442 cases (3.4%), ascending aortic
aneurysms for 286 (2.2%), type A aortic dissections for 135
(1.0%), descending thoracic and thoraco-abdominal aortic
aneurysms for 132 (1.0%), peripheral arterial aneurysms for
85 (0.6%), and type B aortic dissections for 41 (0.3%) (all
aneurysmsZ8.5%). Throughout the 10-year observation
period, EVAR was used in 66/132 descending thoracic and
thoraco-abdominal aortic aneurysms (50%), whereas the
corresponding numbers are 149/442 for the abdominal aorta
(34%). At the beginning of this study period, in 1994, EVAR
was not available, whereas nowadays it is used almost
exclusively for early and late repair of traumatic aortic
ruptures, 50% of descending thoracic aortic aneurysms, and
40% of abdominal aortic aneurysms. The aneurismal lesions
(all) account by now 14.5% of our caseload as compared to
6.6% over the entire period studied (see above).
Interestingly enough, EVAR procedures at the Department
of Cardio-vascular Surgery, CHUV in Lausanne are entirely
performed by the surgical team. As a matter of fact, we rely
only so far on pre-procedural imaging as it is necessary for
the establishment of the diagnosis, and preliminary assess-
ment of feasibility. A mobile cart with the most frequently
used guide-wires, introducers, catheters, and other ancillary
equipment (Fig. 1) can be readily moved to the specific
operating theatre together with the machine for intravas-
cular ultrasound (IVUS), and the C-arm for fluoroscopy. Per-
procedural road-mapping is based on IVUS and fluoroscopy,
which are used for target site identification, neck quality
assessment, and all necessary measurements for device
selection [1]. Straight thoracic aortic, straight abdominal
aortic, tapered aorto-iliac, and bifurcated aorto-iliaccovered stent-grafts are selected out of our in-house stock
(Fig. 2) holding most current device configurations in various
dimensions as well as the corresponding extensions, plugs,
etc. As a result, emergency and semi-elective endo-vascular
procedures can be realized at any time, and in our hands only
very few custom made devices are nowadays necessary for
established EVAR indications. In house developments enhan-
cing indications for EVAR include in situ introducer sheath
dilatation [2] for patients with complex aortic access, as
well as partial inflow occlusion [3] for blood pressure (flow)
control during device positioning and deployment. Finally,
we rely primarily on ultrasonic imaging for early quality
assessment. The techniques described have been
made available to remote teams through tele-medecine
Fig. 2. In-house stock holding most current device configurations for
abdominal (bifurcated grafts (body diameter 23–32 mm) and limbs are
horizontal), aorto-mono-iliac grafts (vertical on the left) and thoracic
(vertical on the right: 24–46 mm in diameter with various lengths) EVAR in
various dimensions as well as the corresponding extensions, plugs, etc.
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on workshop modules (www.heartlab.org).4. Impact for the future
The most limiting factor in EVAR is at this time the
presence of significant aortic branches within the aneurysm
neck or within the aneurysm. Hence, the development of
fenestrated covered stent-grafts allowing for covering aortic
side orifices without compromising side branch blood flow
[5] as well as the design of covered stent-grafts with modular
side branches [6] address both these issues and have the
potential to push the current limits significantly further as
endo-vascular repair of juxtarenal abdominal aortic aneur-
ysms, abdominal aortic aneurysms with suprarenal exten-
sion, thoraco-abdominal aneurysms as well as aortic arch
aneurysms may eventually be cured with such devices. An
interesting development based on the knowledge gathered
from covered stent-grafts, is the already available venous
smart canula for less invasive cardio-pulmonary bypass. The
latter can be inserted over a guide wire through a peripheral
(femoral) vein into the vena cava, and expanded in situ, thus
doubling its cross-sectional area, an effect that allows to
achieve full venous flow based on gravity drainage alone [7].
However, the most spectacular steps forward, were
certainly made in the field of prosthetic heart valve
replacement, where the advent of valved stents could
have a huge impact on the daily practice of cardio-vascular
surgery. For the time being, most non-surgical players in this
field focus on percutaneous access [8,9], which automati-
cally limits the potential candidates for such procedures due
to the limited access vessel diameter and the navigation
problems due tortuous and/or stenosed vessels. However,
despite these difficulties, there have been several reports onclinical applications of valved stents in pulmonary [10] as
well as aortic position [11]. For the latter application, there
still remain a number of issues including the fate of the
coronary arteries [12], and the question whether calcified
valve leaflets should be removed or not. It may also turn out,
that the percutaneous route from the groin or neck is not the
best access to the heart, and that a direct (surgical [13])
mini-invasive approach for antegrade implantation of valved
stents is superior [14,15].5. Conclusions
EVAR is here to stay. New developments are coming in
many ways and stent derived devices can by now be found
everywhere in the cardio-vascular system. This includes
stenosed vessels, aneurysmal vessels, diseased valves, all
sorts of congenital heart defects, and even cardiopulmonary
bypass. Key technology for EVAR is available or can be made
available in most cardio-vascular surgical units. Special
interest in this field (clinical and/or experimental) can
enhance recruitment of patients. The opposite is also true.References
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Dr C. Mestres (Barcelona, Spain): You know, Ludwig (Ludwig von
Segesser), when we think about it, I think the key point is that the surgeon
has to lead the path, and we may agree in collaborating with the radiologist,
or whoever, but the surgeon should be the leader.
Keith Dawkins was telling something current with this, they don’t have
beds, and this is true, it should hold true, because it is a very important point,
which is whoever does an interventional procedure, in many cases, as you
know, that especially interventional guys have gone that way, or radiologists,
they go that way, one thing is to work and dilate angiograms, another thing is
to work and dilate patients, and this is the key point.
This is why the surgeon must always be the leader.
I think we will see many problems in the future, because the problem to
me is that many of the people involved in endovascular work do not know
anything about anatomy, physiology, medicine and surgery of the systems.
Craig Miller was very clear at the Lisbon meeting saying that the problem is
not that we invent a new technology or develop a new technology like
endovascular stenting, it is that who will get the complications that are going
to be in the future. We know almost everything about conventional
prostheses, especially those that still do vascular surgery. They become
infected, they may have complications in the early, mid, and long-term run,
5, 10, 15, 20 years after that, and the problem is, who is going to take those
cases? I think it is the surgeon. So we are learning. Probably endovascular work
is going to be very good in the thoracic sector because of morbidity. This does
not really hold true so far for the abdominal aorta, because we are still
learning and the experiences from the Eurostar registry, they go that way.
So I think the point is that the surgeon must always be the leader. That is
my opinion.
Dr M. Turina (Zurich, Switzerland): I can only support Ludwig’s
statement, the surgeon should stay in control. There is no more embarrassing
field than the ruptured aortic aneurysm, both abdominal and thoracic, and if
you can reduce the mortality of your ruptured abdominal aneurysm below
30%, you are a very good surgeon. Having a system where in the emergency
room we run the CT and immediately perform endoaortic prosthesis, we have
reduced the mortality in the last two years to less than 5% in ruptured
abdominal aortic aneurysms, and the same holds true for thoracic aneurysms,
which are really a challenging task. You yourself, Ludwig, published once a
paper about our ruptured thoracic aneurysms, with substantial mortality.
But I can only make a plea, that endoaortic prostheses is a surgeon’s field,,
and should stay so. Surgeons do not only have the beds, the intensive care, but
also can treat the possible complications. The problems might arise with
internal iliac artery ischemia, or with left subclavian artery ischemia, which
will need carotid to subclavian bypass; and the patients must be closely
followed after the EAP. The radiologists do not have this possibilities, which is
reflected in their publications: very little is known about the patients a year
later.
Dr J. Revuelta (Santander, Spain): I think with Ludwig’s experience we
can learn an important lesson concerning the leadership, as Carlos Mestres
said. Why we or Ludwig are the leaders in endovascular stenting, we are the
leader in Santander in endovascular stenting, is only one reason, because we
have the patients. We have the patients in our out-patient clinics; they are our
patients. So why do we have a problem on the cardiac side? We have a problem
on the cardiac side in Santander. Why they are eating the cake, pacemaker,
defibrillator, coronary surgery, congenital, ASD, you know, all of this, and now
valves, because they have the patients.So as has been explained this morning, our specialty is changing
drastically. And why be afraid about changing, why be afraid about new
revolutions? Probably we started as thoracic surgeons, and then we joined our
forces, and now we are quite separated as cardiac. In Spain only a few centers
are real cardiovascular, only a few, and we will disappear too.
So probably, in my opinion, we need to be where the patients are. So we
must join the cardiologists. And why not? Try to invent a new specialty,
cardiovascular specialty, in the future. Is there any possibility for that? Not
from our side. We tried to convince cardiology that they need to learn how to
put a patient on cardiopulmonary bypass, repair the valve. So as soon as the
future people start learning how to put patients on cardiopulmonary bypass
during surgery, we are inventing a new specialty, cardiovascular specialty,
and this way we have the patients again. Otherwise it will be, in my opinion,
very difficult, and we are just waiting for other people eating our cake.
Dr F. Mohr (Leipzig, Germany): Even if I contradict Ludwig a little bit, I
think we have to acknowledge that the cardiologists at least are more
experienced in catheterization and they understand angiography, at least at
the moment, much better than our specialty.
I do not believe that it is a question of who is in command. I think we have
to form a specialized group like just has been said by Dr Revuelta. A
cardiologist/endosurgeon has to specialize in such treatments, and obviously
the patient together, the two together, both of them have to understand the
endovascular treatment. Otherwise it may well happen that the angiologists
or peripheral angiologists can just do it by themselves. They see their own
patients, they don’t send them to surgery at all, and there will be a complete
percutaneous application possible without the need for exposure of the
femoral arteries or something like that. I think we just have to overcome the
thinking that the surgery has to be done by the cardiac surgeon. I think we just
have to form a team out of two members or three members who really focus
on aneurysms, and the same is true for mitral valves, and put these people
together to get excellent results. Otherwise if you let me try the catheter
technique right now, I have to restudy the whole procedure, and most of us
are not ready to do that.
Dr von Segesser: I do not agree at all. I think the trick is exactly that you
don’t need angiography, and if you don’t need angiography, you don’t need
somebody to do the angiography. You can do these procedures without
angiography. We have done now hundreds without.
Dr R. Bolton (Greenwood, SC, USA): I am hearing the same theme that we
had in the last talk, and that is an ‘us-them’ idea, and I don’t see that at all. I
think that the point of this is looking to the future, and I agree that doing that
is going to take a team approach. I do not care to see all the patients the
cardiologist sees, and I think if we take one little train of endovascular
stenting or maybe it is angiography, or whatever it happens to be, we are
narrowing ourselves and our practice into a very small practice.
I believe personally that we need to be a team approach, and that is that
we develop service lines and we work as a team. I don’t want to screen 100
patients to operate on one. I don’t want to be doing all the other things. And I
do still like to do general thoracic surgery in addition to cardiac surgery. But I
think as we look to the future, we can’t put ourselves in a niche. We have to
work at things as a team and we have to change our process. I was brought up,
as most of us were, in a surgery-oriented service line, and then our medical
colleagues in medicine. It has always been surgery versus medicine, and I
think we have to get past that.
We are in this room, for the predominant part, treating a particular
disease process from start to finish, and it should include everything in
between, and the technologies will be developed. It would be ridiculous to
think that a cardiologist or any other person was going to do endovascular
stenting without some sort of backup, at least initially, because there will be
complications. There are complications whether it is done robotically or in the
cath lab. And what I see after my career is it is going to be a biological
engineered specialty where you get a shot in the arm and the calcium deposits
go away. That is so far beyond me, but it is not beyond our industry colleagues
that are looking at that today.
So those are my comments, for what it is worth, but I think we are kind of
barking up the wrong tree to say that we are going to solve the problems by
thinking, at least in the United States, I honestly don’t see the cardiologists
going away and me taking over their job, and neither do I want to, but I can
work as a team, and we can do things very well together and complement one
another rather than being at odds.
Dr A. Haverich (Hannover, Germany): For this discussion there is one
issue missing, and that is, the patient. I think we should put the patient first in
our thinking and talk about what kind of structure would help the patient to
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approach, because we can learn something from the cardiologists in terms of
bidimensional and black and white type of thinking, and vice versa, I think the
cardiologists may be able to learn something from us like three-dimensional
thinking and also thinking in colors, which may be important.
Now, Keith Dawkins and myself have been knowing each other for the last
20 years, we were fellows together at Stanford, and we had some very good
discussions in the past. I can tell you, Keith, I think it is going to be much easier
to teach a surgeon to do a coronary angiography rather than to teach a
cardiologist to think three-dimensionally for aortic valve repair on an
interventional base.
Again, I think it must be a team approach and this is the way we should
structure that for the future. If we don’t work it as a team approach, the
following scenario will be present, like with PTCA and coronary stents: the
definition of success will vanish. In aortic stenosis, the gradient will drop from
80 to 40, and this will be defined as a success. If there is a leak in that
interventionally placed aortic valve, that will be tolerated, whereas at the
present time no leaks would be tolerated. And the patient selection will be
such that in multicenter trials, the interventional approach will be superior to
the surgical approach, just by selection of the patients. This is the scenario
that will happen, so we have to put our fingers into that scenario.
But again, I would see the best way to do it for the patient and get into a
team approach, and I have no objections if the surgeon would be leading that
team.
Dr T. Aberg (Umea, Sweden): The team approach is organizationally
manifest in the new development of heart centers where all the specialties
work together, and there have been some spectacular successes with the
organizational forum of the heart center.
Dr D. Cosgrove (Cleveland, OH, USA): I think that you are going to realize
in the United States that the patients who have cardiac disease are controlled
by the cardiologists, and if the cardiologists are given the tools,the cardiologists are going to use them, and I think basically we have to
decide, are we going to be surgeons or are we going to be cardiologists, and if
you want to be a catheter-based therapist, I think you might be better off
following that specialty which is designed to train.
Now, I don’t think that applies to aortic disease. In aortic disease surgeons
control the patients and the surgeons have the decision whether they are
going to operate on them or they are going to use stenting or endovascular
techniques, and I think that is perfectly appropriate, but it is certainly totally
different for cardiac disease in the United States. We don’t have the specialty
training, we don’t have the licensure to go into the cath lab, we don’t control
the cath lab, we don’t control the patient, and to think that we are going to
change that is, in the United States anyhow, a fallacy. And more importantly,
we have to decide how we want to spend our days: do we want to wear a mask
or do we want to wear lead?
Mr T. Treasure (London, UK): I am much more interested in the team
focusing on what is best for the patient. In the case of thoracic aortic disease
and the use of stents, the work is being done in a team: vascular radiology
cardiothoracic and vascular surgeons who have (in our case) a sort of arbitrary
division at the diaphragm.
Lung cancer similarly. The surgeon has a role in diagnosis, in staging, and
in resection. Because resection is only appropriate for a minority of lung
cancer, management is inevitably a team approach. All the cases are
discussed, and the best combination of diagnostic staging and treatment
strategies is put together for that patient. No camps. No sides.
Cardiac surgery used to be like that when I started. We discussed every
case, valves or coronaries, and we put together a plan whether for continued
monitoring or that it was time for surgery, and we did that the whole time.
That is one of the things which I missed more and more in the last, say, five
years of doing cardiac surgery. I have regained in my present work in the last
four years in thoracic surgery. I am back with a team, and it is a more
enjoyable and better way to work.
